Anja Hohmann

Anja Hohmann has over 10 years of experience in the biopharmaceutical industry. Anja began their career in 2010 as a Master Student at the MRC Laboratory of Molecular Biology (LMB). In 2011, they became a PhD Student at Cold Spring Harbor Laboratory, where they identified BRD9 as a selective cancer dependency in leukemia by loss-of-function RNAi screening in murine and human leukemia cells, revealed Myc as a key target gene of BRD9 in leukemia cells by RNA- and ChIP-Seq analysis, and used flow cytometry and confocal microscopy to demonstrate a role for BRD9 in preventing leukemia blast differentiation. In 2016, they joined KSQ Therapeutics, Inc. as a Senior Scientist, Target Discovery and subsequently held the positions of Associate Principal Scientist and Principal Scientist. In 2020, they moved to Constellation Pharmaceuticals as an Associate Director, Discovery Biology, and in 2021 they were appointed Director, Cell Therapies at Be Biopharma.

Anja Hohmann completed their Doctor of Philosophy (PhD) in Biology at Cold Spring Harbor Laboratory in 2016. Prior to this, they obtained their Master of Natural Sciences (MSci) in Biochemistry from the University of Cambridge in 2011. Anja also earned their Bachelor of Arts (BA) in Biochemistry from the University of Cambridge in 2010. In 2015, they obtained an additional certification in Managing Science in the Biotech Industry from the Keck Graduate Institute.